Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATIC | P31939 | 1/20 | 0.66 |
| ▸ | NPC1L1 | Q9UHC9 | 3/20 | 0.61 |
| ▸ | USP2 | O75604 | 3/20 | 0.58 |
| ▸ | RORC | P51449 | 3/20 | 0.58 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | OSBP | P22059 | 1/20 | 0.58 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.54 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
| ▸ | RORA | P35398 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olesoxime SCHEMBL19668134 | 1.00 | ATIC (0.66) | ATICNPC1L1USP2RORCCYP46A1 | |
| Olesoxime SCHEMBL18870340 | 1.00 | ATIC (0.66) | ATICNPC1L1USP2RORCCYP46A1 | |
| Olesoxime SCHEMBL1010552 | 1.00 | ATIC (0.66) | ATICNPC1L1USP2RORCCYP46A1 | |
| Olesoxime SCHEMBL19236075 | 1.00 | ATIC (0.66) | ATICNPC1L1USP2RORCCYP46A1 | |
| Olesoxime SCHEMBL19668133 | 1.00 | ATIC (0.66) | ATICNPC1L1USP2RORCCYP46A1 | |
| Olesoxime SCHEMBL19668128 | 1.00 | ATIC (0.66) | ATICNPC1L1USP2RORCCYP46A1 | |
| SCHEMBL20787615 | 0.91 | ATIC (0.67) | ATICNPC1L1USP2RORCCYP46A1 | |
| SCHEMBL20787613 | 0.91 | ATIC (0.67) | ATICNPC1L1USP2RORCCYP46A1 | |
| SCHEMBL20787612 | 0.91 | ATIC (0.67) | ATICNPC1L1USP2RORCCYP46A1 | |
| SCHEMBL20787614 | 0.91 | ATIC (0.67) | ATICNPC1L1USP2RORCCYP46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 495 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440466-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2025-10-14 | — | — | US | claimed |
| US-20250295614-A1 | COMPOSITIONS FOR PREVENTING TRANSITION FROM ACUTE TO CHRONIC PAIN | UNIV CALIFORNIA (US) | 2025-09-25 | — | — | US | claimed |
| EP-4583859-A2 | COMPOSITIONS FOR PREVENTING TRANSITION FROM ACUTE TO CHRONIC PAIN | The Regents of University of California (US) | 2025-07-16 | — | — | EP | claimed |
| WO-2025088514-A1 | METTL3-METTL14-COMPLEX INHIBITORS FOR THE TREATMENT OF NEUROMUSCULAR DEGENERATIVE PATHOLOGIES CAUSED BY OR LINKED TO MUTATIONS IN THE FUS GENE | Università degli Studi di Roma “La Sapienza” (IT) | 2025-05-01 | — | — | WO | claimed |
| WO-2025059302-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT AND MODULATION OF ACUTE AND CHRONIC SYMPTOMS OF MITOCHONDRIAL DISEASE AND DYSFUNCTION | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-03-20 | — | — | WO | claimed |
| US-20250000817-A1 | Methods of Treating Mitochondrial Dysfunction | RIBONOVA INC. (US) | 2025-01-02 | — | — | US | claimed |
| US-12102633-B2 | Spirolactone compounds | QUIXGEN, INC. (US) | 2024-10-01 | — | — | US | claimed |
| US-20240252486-A1 | ALGOSTATIC AGENTS FOR PREVENTING TRANSITION FROM ACUTE TO CHRONIC PAIN | UNIV CALIFORNIA (US) | 2024-08-01 | — | — | US | claimed |
| EP-4003314-B1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | claimed |
| EP-4397369-A2 | METHODS OF TREATING MITOCHONDRIAL DYSFUNCTION | Ribonova Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| US-7858603-B2 | neuroprotectants such as 1,4-cholestadien-3-one oxime, used for the treatment of neurodegenerative diseases | TROPHOS (FR) | 2010-12-28 | — | — | US | claimed |
| US-20100310674-A1 | NOVEL COMPOSITION FOR TREATING THE SIDE EFFECTS OF ANTICANCER TREATMENTS | TROPHOS (FR) | 2010-12-09 | — | — | US | claimed |
| US-20100267680-A1 | USE OF AT LEAST ONE OXIME DERIVATIVE OF CHOLEST-4-EN-3-ONE AS ANTIOXIDANTS | TROPHOS (FR) | 2010-10-21 | — | — | US | claimed |
| US-20100216752-A1 | USE AS MEDICAMENTS OF DERIVATIVES OF CHOLEST-4-EN-3-ONE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, NOVEL DERIVATIVES AND THEIR PREPARATION PROCESS | TROPHOS (FR) | 2010-08-26 | — | — | US | claimed |
| US-20100099652-A1 | NOVEL COMPOSITION BASED ON CHOLEST-4-EN-3-ONE OXIME | TROPHOS (FR) | 2010-04-22 | — | — | US | claimed |
| WO-2010012904-A2 | NOVEL CHOLEST-4-EN-3-ONE OXIME DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND PREPARATION METHOD | TROPHOS (FR) | 2010-02-04 | — | — | WO | claimed |
| US-20090186863-A1 | USE OF CHOLEST-4-EN-3-ONE DERIVATIVES FOR OBTAINING A CYTOPROTECTIVE DRUG | TROPHOS (FR) | 2009-07-23 | — | — | US | claimed |
| EP-1963355-A2 | NEW CHOLEST-4-EN-3-ONE OXIME DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND PREPARATION PROCESS | Trophos (FR) | 2008-09-03 | — | — | EP | claimed |
| WO-2007080270-A2 | NEW CHOLEST-4-EN-3-ONE OXIME DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND PREPARATION PROCESS | TROPHOS (FR) | 2007-07-19 | — | — | WO | claimed |
| US-20060217358-A1 | Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof | TROPHOS (FR) | 2006-09-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267680-A1 | USE OF AT LEAST ONE OXIME DERIVATIVE OF CHOLEST-4-EN-3-ONE AS ANTIOXIDANTS | ACOX3, GSTO1, GPX4 | ATIC 3690/4885NPC1L1 80/4885USP2 2161/4885 |
| US-20100099652-A1 | NOVEL COMPOSITION BASED ON CHOLEST-4-EN-3-ONE OXIME | CETP, ELOVL3, MTTP | ATIC 4878/4885NPC1L1 72/4885USP2 3400/4885 |
| US-20100216752-A1 | USE AS MEDICAMENTS OF DERIVATIVES OF CHOLEST-4-EN-3-ONE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, NOVEL DERIVATIVES AND THEIR PREPARATION PROCESS | CYP27A1, NLN, NPC1 | ATIC 4625/4885NPC1L1 25/4885USP2 3916/4885 |
| US-20250000817-A1 | Methods of Treating Mitochondrial Dysfunction | SLC25A20, NDUFAB1, HAGH | ATIC 4321/4885NPC1L1 258/4885USP2 1654/4885 |
| US-12102633-B2 | Spirolactone compounds | ACACA, AKR1C2, AKR1A1 | ATIC 3422/4885NPC1L1 557/4885USP2 3544/4885 |
| US-20090186863-A1 | USE OF CHOLEST-4-EN-3-ONE DERIVATIVES FOR OBTAINING A CYTOPROTECTIVE DRUG | NPC1, CYP27A1, NPC1L1 | ATIC 4835/4885NPC1L1 3/4885USP2 2589/4885 |
| US-20060217358-A1 | Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof | CYP46A1, NR1H4, CYP27A1 | ATIC 3537/4885NPC1L1 28/4885USP2 3959/4885 |
| US-12440466-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | CPT1A, NR1H2, NR1H3 | ATIC 1479/4885NPC1L1 211/4885USP2 2722/4885 |
| US-20100310674-A1 | NOVEL COMPOSITION FOR TREATING THE SIDE EFFECTS OF ANTICANCER TREATMENTS | HCCS, CYP27A1, CETP | ATIC 4720/4885NPC1L1 38/4885USP2 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.